Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has announced an update regarding its ongoing share buy-back program. As of September 26, 2025, the company has repurchased a total of 1,476,163 ordinary fully paid securities, with 74,423 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting positively on its market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$285.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma-derived therapies and influenza vaccines, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,131,613
Technical Sentiment Signal: Sell
Current Market Cap: A$95.74B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.